Canaccord Genuity Reiterates a 'Buy' on Orexigen Therapeutics (OREX); OREX Shoots and Scores; FDA Panel Gives Contrave a Big Fat Yes
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Orexigen Therapeutics (NASDAQ: OREX), raises PT from $14 to $19.
Canaccord analyst says, "Yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
